Baird lowered the firm’s price target on Jazz Pharmaceuticals to $154 from $160 and keeps an Outperform rating on the shares. The firm said Q2 revenue was in line with expectations, though the company slightly narrowed 2024 total revenue guidance as Epidiolex revenue showed particular strong growth, while Rylaze appeared to be the weak spot in revenue.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance
- Needham healthcare analysts hold analyst/industry conference call
- JAZZ Upcoming Earnings Report: What to Expect?
- Truist healthcare analyst holds an analyst/industry conference call
- Jazz Pharmaceuticals price target lowered to $150 from $160 at Morgan Stanley